{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:40Z","timestamp":1786119580422,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/jcp.0b013e3182664ecd","type":"journal-article","created":{"date-parts":[[2012,8,25]],"date-time":"2012-08-25T02:44:07Z","timestamp":1345862647000},"page":"666-671","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment"],"prefix":"10.1097","volume":"32","author":[{"given":"Mohammad-Reza","family":"Shiran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Lennard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Zafar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale","family":"Lagundoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Seivewright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Rostami-Hodjegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10550887.2010.531672","article-title":". Effect of methadone maintenance treatment on heroin craving, a literature review.","volume":"30","author":"Fareed","year":"2011","journal-title":"J Addict Dis"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugpo.2009.10.004","article-title":"Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings.","volume":"21","author":"Bruce","year":"2010","journal-title":"Int J Drug Policy"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/JCP.0b013e3181e6df49","article-title":". Effects of a single 50 extra dose of methadone on heroin craving and mood in lower- versus higher-dose methadone patients.","volume":"30","author":"Strasser","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1360-0443.1997.tb02866.x","article-title":"Patterns of symptom complaints in methadone maintenance patients.","volume":"92","author":"Dyer","year":"1997","journal-title":"Addiction"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","article-title":". Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.","volume":"65","author":"Dyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00004714-200102000-00014","article-title":". The relationship between mood state and plasma methadone concentration in maintenance patients.","volume":"21","author":"Dyer","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.1987.47","article-title":". Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain.","volume":"41","author":"Inturrisi","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/clpt.1990.77","article-title":". Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain.","volume":"47","author":"Inturrisi","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","article-title":"Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.","volume":"70","author":"Boulton","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0b013e318192eb00","article-title":". Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.","volume":"29","author":"Elkader","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(03)00190-X","article-title":". Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence.","volume":"72","author":"Mitchell","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0022-3565(25)38315-1","article-title":"Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats.","volume":"266","author":"Ekblom","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0022-3565(25)39480-2","article-title":". Quantification of effect delay and acute tolerance development to morphine in the rat.","volume":"267","author":"Gardmark","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0028-3908(86)90255-8","article-title":"Unequal opiate cross-tolerance to morphine in the locomotor-activation model in the mouse.","volume":"25","author":"Brase","year":"1986","journal-title":"Neuropharmacology"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)10719-2","article-title":"Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.","volume":"262","author":"Paronis","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","article-title":"Methadone: a review of its pharmacokineticpharmacodynamic properties.","volume":"42","author":"Garrido","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":". Two new rating scales for opiate withdrawal.","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0376-8716(99)00117-9","article-title":"Validation of The Christo Inventory for Substance-misuse Services (CISS): a simple outcome evaluation tool.","volume":"59","author":"Christo","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/01.ftd.0000164392.01779.db","article-title":"Iqbal MZ, et al..","volume":"27","author":"Shiran","year":"2005","journal-title":"Can saliva replace plasma for the monitoring of methadone Ther Drug Monit"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":". Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.","volume":"67","author":"Shiran","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1570-0232(02)00673-6","article-title":". Determination of midazolam and 1-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment.","volume":"783","author":"Shiran","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02245829","article-title":". Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients.","volume":"118","author":"Hiltunen","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0b013e318192eb00","article-title":". Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.","volume":"29","author":"Elkader","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5694\/j.1326-5377.1991.tb121030.x","article-title":"Methadone dosage and retention of patients in maintenance treatment.","volume":"154","author":"Caplehorn","year":"1991","journal-title":"Med J Aust"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":". Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.","volume":"281","author":"Strain","year":"1999","journal-title":"JAMA"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archpsyc.57.4.395","article-title":"Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance.","volume":"57","author":"Preston","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hup.630","article-title":". The effects of methadone and its role in fatalities.","volume":"19","author":"Corkery","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R29-13-20210128","first-page":"404","article-title":". When enough is not enough: new perspectives on optimal methadone maintenance dose.","volume":"67","author":"Leavitt","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/02791072.1999.10471730","article-title":"Optimizing response to methadone maintenance treatment: use of higher-dose methadone.","volume":"31","author":"Maxwell","year":"1999","journal-title":"J Psychoactive Drugs"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000018936","article-title":". L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations.","volume":"4","author":"de Vos","year":"1998","journal-title":"Eur Addict Res"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0024-3205(97)00367-6","article-title":". Extraordinary potency of a novel delta opioid receptor agonist is due in part to increased efficacy.","volume":"61","author":"Kramer","year":"1997","journal-title":"Life Sci"},{"key":"R33-13-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1124\/mol.58.4.863","article-title":"Mdr1 limits CYP3A metabolism in vivo.","volume":"58","author":"Lan","year":"2000","journal-title":"Mol Pharmacol"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00213-003-1718-1","article-title":". Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice.","volume":"173","author":"Wang","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1002\/jps.21770","article-title":". Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.","volume":"98","author":"Hassan","year":"2009","journal-title":"J Pharm Sci"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1067\/mcp.2002.128388","article-title":"Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.","volume":"72","author":"Cummins","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0041-008X(78)90174-6","article-title":"Electroencephalographic and behavioral tolerance and cross-tolerance to morphine and methadone in the rat.","volume":"45","author":"Meltzer","year":"1978","journal-title":"Toxicol Appl Pharmacol"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00005053-197802000-00004","article-title":". Methadone dose, plasma level, and cross-tolerance to heroin in man.","volume":"166","author":"Volavka","year":"1978","journal-title":"J Nerv Ment Dis"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(85)90539-4","article-title":"Effects of acute and chronic morphine treatment on methadone analgesia and metabolism.","volume":"109","author":"Liu","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0022-3565(25)10715-5","article-title":". mu-Opioid receptor regulation during opioid tolerance and supersensitivity in rat central nervous system.","volume":"274","author":"Diaz","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-200201000-00001","article-title":"A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans.","volume":"12","author":"Hollt","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R43-13-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00008571-200201000-00002","article-title":". The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constricting effect of morphine-6-glucuronide but not that of morphine.","volume":"12","author":"Lotsch","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00008571-200309000-00001","article-title":"Drug receptoreffector polymorphisms and pharmacogenetics: current status and challenges.","volume":"13","author":"Johnson","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JCP.0b013e3182664ecd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:38:57Z","timestamp":1786041537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201210000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182664ecd","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}